Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacy-based feasibility trial of Tripalma vs Crystaderm for childhood impetigo
ACTRN12621000403831Phase 2Withdrawn
- Sponsor
- Manuka Bioscience
- Start
- Jun 2021
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in impetigo comparing Tripalma with Crystaderm active control (2 arms). Primary endpoint: Proportion of screened participants randomized. Planned start Jun 2021; status: withdrawn.
02
Drugs
Tripalmahydrogen peroxide
03
Conditions
impetigo
Beyond the preview
Go deeper on ACTRN12621000403831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000403831.